Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Narrative) (Details)

v3.21.2
Fair Value Measurements (Narrative) (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock, value $ 97 $ 95  
Caelum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair value of investment $ 48,500   $ 48,500
Caelum [Member] | Share Price [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investment, measurement input | $ / shares 6.717   6.717
Caelum [Member] | Risk Free Interest Rate [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investment, measurement input 0.0087    
Caelum [Member] | Expected Volatility [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investment, measurement input 0.70    
Caelum [Member] | Discount for Lack of Marketability [Member] | Minimum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investment, measurement input 0.137    
Caelum [Member] | Discount for Lack of Marketability [Member] | Maximum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investment, measurement input 0.30    
Journey [Member] | DFD Agreement [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock, value $ 150,000    
Journey [Member] | DFD Agreement [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are Met [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock, value $ 5,000    
Journey [Member] | DFD Agreement [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Contingent Conditions are not Met [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Contingent payment warrants, agreement terms Journey or its affiliate executes a definitive agreement for an acquisition event during the period beginning on the Effective Date and ending twenty-four (24) months after the regulatory approval of DFD-29, Journey shall pay to DRL: (a) 20% of the value of DFD-29 attributable to the acquisition event, if such acquisition event occurs between closing and NDA approval; or (b) 12% of the value of DFD-29 attributable to the acquisition event, if such acquisition event occurs within 24 months after    
Placement Agent Warrants [Member] | Journey [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Warrants, value $ 500    
Contingent Payment Warrant [Member] | Journey [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Warrants, value $ 3,700 $ 0